AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
AMARIN CORP PLC\UK
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$11.53+0.21 (+1.86%)
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
AMARIN CORP PLC\UK revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue, Net | $182.75M | $204.59M | $285.30M | $366.51M | $580.32M | $607.03M | $427.39M | $228.37M | $179.83M | $128.97M | 85.5% | -10.7% |
| Licensing and Royalty Revenue | $30.89M | $24.02M | $21.61M | $2.68M | $2.87M | $7.04M | $2.36M | $843.00K | – | – | 14.5% | +28.6% |
| Licensing Revenue | – | – | – | – | – | – | $2.36M | $843.00K | $1.28M | $1.12M | – | – |
By region
From the segment and revenue-disaggregation notes of Amarin Corp Plc\Uk's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.